BioSpace News Archive

EnPro Industries, Inc. (NYSE: NPO) intends to release financial results for the third quarter of 2021 on Friday, November 5, 2021, before the opening of trading on the New York Stock Exchange.

Veracyte, Inc. (Nasdaq: VCYT) announced today that new data being presented at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting suggest the company’s Decipher Prostate genomic classifier identifies patients with clinically high-risk prostate cancer who may require treatment intensification beyond standard-of-care therapy.

Humanigen, Inc. (Nasdaq: HGEN), today announced the European Commission identified lenzilumab as one of the “10 most promising treatments for COVID-19” in a report and press release issued on October 22, 2021.

Taking place for the first time since October 2019, CPhI Worldwide will return in-person on 9-11 November 2021 at Fiera Milano in Milan, Italy.

Air Products (NYSE: APD), a global leader in industrial gases and cryogenic technology, and Sublime Stericeuticals Corporation, a process design and equipment manufacturer serving the pharmaceutical industry, today announced plans to collaborate and develop a proprietary sublimation and desorption technology for a continuous freeze-drying system for vaccine and drug solutions.

About half of patients with appendicitis do not need an appendectomy procedure up to four years after receiving a course of antibiotics, according to final results of the Comparison of Outcomes of antibiotic Drugs and Appendectomy (CODA) trial.

SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, November 8, 2021, at 8:00 a.m. ET to provide a corporate update and results for the third quarter of 2021.

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced interim clinical data from the Phase 1/2 clinical trial of intravenous 4D-310 in patients with Fabry disease.

Erasca, Inc. (Nasdaq: ERAS), today announced the presentation of preclinical data for ERAS-801, a small molecule epidermal growth factor receptor (EGFR) inhibitor specifically designed to have high central nervous system (CNS) penetration for the treatment of glioblastoma multiforme (GBM), at the American Association for Cancer Research (AACR) Special Virtual Conference on Brain Cancer.